KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Amortization - Intangibles: 2015-2016

Historic Amortization - Intangibles for Teva Pharmaceutical Industries (TEVA) over the last 2 years, with Dec 2016 value amounting to $6.5 billion.

  • Teva Pharmaceutical Industries' Amortization - Intangibles rose 16.20% to $7.5 billion in Q3 2017 from the same period last year, while for Sep 2017 it was $21.3 billion, marking a year-over-year change of. This contributed to the annual value of $6.5 billion for FY2016, which is 9.89% up from last year.
  • As of FY2016, Teva Pharmaceutical Industries' Amortization - Intangibles stood at $6.5 billion, which was up 9.89% from $5.9 billion recorded in FY2015.
  • Teva Pharmaceutical Industries' 5-year Amortization - Intangibles high stood at $6.5 billion for FY2016, and its period low was $5.9 billion during FY2015.
  • For the 2-year period, Teva Pharmaceutical Industries' Amortization - Intangibles averaged around $6.2 billion, with its median value being $6.2 billion (2015).
  • Data for Teva Pharmaceutical Industries' Amortization - Intangibles shows a peak YoY rose of 9.89% (in 2016) over the last 5 years.
  • Yearly analysis of 2 years shows Teva Pharmaceutical Industries' Amortization - Intangibles stood at $5.9 billion in 2015, then grew by 9.89% to $6.5 billion in 2016.